Targovax – Therapeutic cancer vaccines

Targovax is an innovation driven specialist in immuno-oncology.

People with identical cancer diagnoses do not have identical diseases. Their cells vary in the way they look, function and are seen by the immune system – the body’s own defence against cancer. At Targovax, we are developing cancer specific therapies that activate each patient’s own immune system to fight against their disease.

Read more

"Even in late stage cancer patients with low immunogenic tumor types, our virus-based immunotherapy can reinstate the immune system’s ability to recognise and attack cancer cells. In addition, studies with our peptide-based Immunotherapy have shown immune responses in difficult to treat RAS cancer patients."

Sari Pesonen, Vice President, Preclinical Research & Clinical Science, Targovax

Read more

Hear from Magnus Jäderberg, CMO of Targovax on PharmaTV why its immuno-oncology pipeline offers something both different and complementary to the most exciting recent advances in this field.

Read more
  • Exercise of employee share options in Targovax ASA

    April 29, 2016

    Reference is made to stock exchange notice of 14 April 2016 regarding increase of the share capital in Targovax ASA (the "Company") relating to exercise of employee options. As per 29 April 2016, 21,559 shares each with a par value of NOK 0.10 were subscribed by employees, including certain former e (...)

    Read more
  • Targovax ASA: Grant of restricted stock units to the Board of directors

    April 15, 2016

    Reference is made to the minutes from the ordinary general meeting in Targovax ASA (the company) regarding the remuneration to be paid to the board of directors and the implementation of a restricted stock unit (RSU) program for the board of directors.

    Under the RSU program, the board of directors  (...)

    Read more
  • Targovax reports immune response with reduced number of TG01 vaccinations

    April 14, 2016

    Oslo 14 April 2016 - Targovax has conducted an interim DTH immunological response evaluation assessing early immune activation following administration of TG01 in combination with gemcitabine in the ongoing Phase I/II trial. The results show that the modified and reduced vaccination schedule generat (...)

    Read more
  • Resolution to increase the share capital in Targovax ASA in relation to exercise of employee options

    April 14, 2016

    To facilitate the exercise of vested employee options in Targovax ASA (the "Company"), the board of directors of the Company has on 14 April 2016, in accordance with the authorisation granted by the general meeting 14 September 2015, resolved to increase the share capital of up to NOK 59,836.60 by i (...)

    Read more
  • Targovax ASA: Protocol from the Annual General Meeting

    April 13, 2016

    The annual general meeting was held on April 13, 2016 at the Company's offices at Lilleakerveien 2C, 0283 Oslo.

    Please find minutes of the meeting attached.

    For further information, please contact:

    Gunnar Gårdemyr
    Phone: +41 798 340 585
    Email: ggardemyr@targovax.com

    Øystein Soug
    Phone: +47 (...)

    Read more
  • Targovax to present at forthcoming Life Science and Investor conferences

    March 14, 2016

    Oslo 14 March 2016 - Targovax, a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announces that members of its senior management team will participate in the following life sciences and investor conferences:


    Sac (...)

    Read more